Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3.

Nicholette A Zeliadt, Laura J Mauro, Elizabeth V Wattenberg
Author Information
  1. Nicholette A Zeliadt: Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Mayo Mail Code #807, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

Abstract

Mitogen activated protein kinase phosphatase-3 (MKP-3) is a putative tumor suppressor. When transiently overexpressed, MKP-3 dephosphorylates and inactivates extracellular signal regulated kinase (ERK) 1/2. Little is known about the roles of endogenous MKP-3, however. We previously showed that MKP-3 is upregulated in cell lines that express oncogenic Ras. Here we tested the roles of endogenous MKP-3 in modulating ERK1/2 under conditions of chronic stimulation of the Ras/Raf/MEK1/2/ERK1/2 pathway by expression of oncogenic Ras. We used two cell lines: H-ras MCF10A, breast epithelial cells engineered to express H-Ras, and DLD-1, colon cancer cells that express endogenous Ki-Ras. First, we found that MKP-3 acts in a negative feedback loop to suppress basal ERK1/2 when oncogenic Ras stimulates the Ras/Raf/MEK1/2/ERK1/2 cascade. ERK1/2 was required to maintain elevated MKP-3, indicative of a negative feedback loop. Accordingly, knockdown of MKP-3, via siRNA, increased ERK1/2 phosphorylation. Second, by using siRNA, we found that MKP-3 helps establish the sensitivity of ERK1/2 to extracellular activators by limiting the duration of ERK1/2 phosphorylation. Third, we found that the regulation of ERK1/2 by MKP-3 is countered by the complex regulation of MKP-3 by ERK1/2. Potent ERK1/2 activators stimulated the loss of MKP-3 within 30 min due to an ERK1/2-dependent decrease in MKP-3 protein stability. MKP-3 levels recovered within 120 min due to ERK1/2-dependent resynthesis. Preventing MKP-3 resynthesis, via siRNA, prolonged ERK1/2 phosphorylation. Altogether, these results suggest that under the pressure of oncogenic Ras expression, MKP-3 reins in ERK1/2 by serving in ERK1/2-dependent negative feedback pathways.

References

  1. Science. 1999 Nov 12;286(5443):1374-7 [PMID: 10558995]
  2. Nat Biotechnol. 2004 Mar;22(3):326-30 [PMID: 14758366]
  3. J Biol Chem. 2004 Aug 6;279(32):33085-92 [PMID: 15159408]
  4. Toxicol Appl Pharmacol. 2002 Nov 15;185(1):8-17 [PMID: 12460732]
  5. Cell Signal. 2004 Jul;16(7):769-79 [PMID: 15115656]
  6. EMBO J. 1996 Jul 15;15(14):3621-32 [PMID: 8670865]
  7. J Biol Chem. 2004 Oct 1;279(40):41882-91 [PMID: 15269220]
  8. Oncogene. 2007 May 14;26(22):3203-13 [PMID: 17496916]
  9. Nat Genet. 2005 Jan;37(1):48-55 [PMID: 15608639]
  10. J Biol Chem. 1996 Mar 15;271(11):6497-501 [PMID: 8626452]
  11. Cancer Res. 2006 Jun 1;66(11):5950-9 [PMID: 16740736]
  12. Nature. 1983 May 5-11;303(5912):72-4 [PMID: 6843661]
  13. J Biol Chem. 2004 Oct 22;279(43):44731-9 [PMID: 15284227]
  14. Nat Rev Cancer. 2003 Jan;3(1):11-22 [PMID: 12509763]
  15. J Biol Chem. 1999 Sep 10;274(37):26563-71 [PMID: 10473620]
  16. FEBS Lett. 1998 Mar 27;425(2):271-6 [PMID: 9559664]
  17. J Biol Chem. 2003 Jan 31;278(5):2903-12 [PMID: 12419823]
  18. Nature. 1987 May 28-Jun 3;327(6120):293-7 [PMID: 3587348]
  19. J Dermatol Sci. 1998 May;17(1):1-7 [PMID: 9651822]
  20. Toxicol Appl Pharmacol. 2003 Nov 1;192(3):212-21 [PMID: 14575638]
  21. Mol Cell Biol. 2005 Jan;25(2):854-64 [PMID: 15632084]
  22. J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56 [PMID: 11897507]
  23. Science. 1993 Apr 2;260(5104):85-8 [PMID: 8465203]
  24. J Cell Sci. 1998 Nov;111 ( Pt 22):3389-99 [PMID: 9788880]
  25. J Biol Chem. 1997 Jul 4;272(27):16917-23 [PMID: 9202001]
  26. Blood. 2003 Oct 1;102(7):2581-92 [PMID: 12791645]
  27. Oncogene. 2007 May 14;26(22):3279-90 [PMID: 17496922]
  28. J Biol Chem. 1996 Feb 23;271(8):4319-26 [PMID: 8626780]
  29. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12759-64 [PMID: 14566055]
  30. Dev Dyn. 2005 Mar;232(3):695-708 [PMID: 15704110]
  31. Endocrinology. 2006 Oct;147(10):4931-40 [PMID: 16840544]
  32. Am J Pathol. 2003 Jun;162(6):1807-15 [PMID: 12759238]
  33. Cell. 1995 Jan 27;80(2):179-85 [PMID: 7834738]
  34. Mol Cell Biol. 2008 Jan;28(1):511-27 [PMID: 17967895]
  35. FASEB J. 2000 Jan;14(1):6-16 [PMID: 10627275]
  36. Chem Rev. 2001 Aug;101(8):2449-76 [PMID: 11749383]
  37. Development. 2004 Jun;131(12):2769-79 [PMID: 15142973]
  38. Br J Cancer. 2005 Aug 8;93(3):310-8 [PMID: 16012519]
  39. J Biol Chem. 1995 Mar 31;270(13):7197-203 [PMID: 7535768]
  40. J Biol Chem. 1999 Feb 12;274(7):4347-53 [PMID: 9933637]
  41. J Biol. 2006;5(5):14 [PMID: 16805921]
  42. Development. 2007 Jan;134(1):167-76 [PMID: 17164422]
  43. J Biol. 2006;5(5):12 [PMID: 16879720]
  44. Nat Cell Biol. 2002 Aug;4(8):556-64 [PMID: 12134156]
  45. Nat Cell Biol. 2003 Jun;5(6):513-9 [PMID: 12766772]
  46. J Biol Chem. 1998 Apr 10;273(15):9323-9 [PMID: 9535927]
  47. Biochem J. 2000 Dec 15;352 Pt 3:701-8 [PMID: 11104676]

Grants

  1. R01 CA104609-02/NCI NIH HHS
  2. R01 CA104609-04/NCI NIH HHS
  3. R01 CA104609/NCI NIH HHS
  4. R01 CA104609-03/NCI NIH HHS
  5. R01-CA104609/NCI NIH HHS
  6. R01 CA104609-01A1/NCI NIH HHS

MeSH Term

Cell Line, Tumor
Dual Specificity Phosphatase 6
Genes, ras
Humans
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Phosphorylation

Chemicals

Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
DUSP6 protein, human
Dual Specificity Phosphatase 6

Word Cloud

Created with Highcharts 10.0.0MKP-3ERK1/2kinaseoncogenicRasproteinextracellularendogenousexpressfoundnegativefeedbacksiRNAphosphorylationregulationERK1/2-dependentactivatedphosphatase-3signalregulated1/2rolescellRas/Raf/MEK1/2/ERK1/2expressioncellsloopviaactivatorswithinmindueresynthesisMitogenputativetumorsuppressortransientlyoverexpresseddephosphorylatesinactivatesERKLittleknownhoweverpreviouslyshowedupregulatedlinestestedmodulatingconditionschronicstimulationpathwayusedtwolines:H-rasMCF10AbreastepithelialengineeredH-RasDLD-1coloncancerKi-RasFirstactssuppressbasalstimulatescascaderequiredmaintainelevatedindicativeAccordinglyknockdownincreasedSecondusinghelpsestablishsensitivitylimitingdurationThirdcounteredcomplexPotentstimulatedloss30decreasestabilitylevelsrecovered120PreventingprolongedAltogetherresultssuggestpressurereinsservingpathwaysReciprocalmitogen

Similar Articles

Cited By